Medication-related impulse control and repetitive behaviors in Parkinson's disease

Current Opinion in Neurology

Volumn 20, Issue 4, 2007, Pages 484-492

  Voon, Valerie ^a,b   Potenza, Marc N ^c   Thomsen, Teri ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Compulsive shopping; Hypersexuality; Impulse control disorders; Parkinson's disease; Pathological gambling

Indexed keywords

APOMORPHINE; CABERGOLINE; CLOZAPINE; COCAINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; QUETIAPINE;

CLINICAL TRIAL; COMPULSION; DISEASE PREDISPOSITION; EATING DISORDER; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; LITERATURE; NEUROBIOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; PHYSICIAN; REVIEW; SENSITIZATION; SHOPPING;

ANTIPARKINSON AGENTS; COMPULSIVE BEHAVIOR; DOPAMINE AGONISTS; HUMANS; IMPULSE CONTROL DISORDERS; NEURONAL PLASTICITY; PARKINSON DISEASE; RECEPTORS, DOPAMINE; REWARD; STEREOTYPED BEHAVIOR;

EID: 34447329280     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32826fbc8f     Document Type: Review

References (49)

1. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathological gambling and medication association in Parkinson's disease. Neurology 2006; 66:1750-1752.
2. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63:969-973. This study systematically assesses the prevalence rates of the ICBs in Parkinson's disease and their relationship with medication status.
3. Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch Neurol 2006; 63:298.
4. Avanzi M, Baratti M, Cabrini S, et al. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006; 21:2068-2072.
5. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 2006; 21:2206-2208.
6. Voon V, Hassan K, Zurowski M, et al. Prevalence of reward-based and repetitive behaviors in Parkinson's disease. Neurology 2006; 67:1254-1257. This study systematically assesses the prevalence rates of ICBs in Parkinson's disease and their relationship with medication status.
7. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21:524-529.
8. Evans AH, Katzenschlager R, Paviour DC, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19:397-405.
9. Miyasaki JM, Hassan K, Lang AE, Voon V. A prospective survey of punding in Parkinson's disease. Mov Disord 2007; 17 January [Epub ahead of print].
10. Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68:423-428.
11. Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005; 20:77-81.
12. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2:595-604.
13. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic medication-related pathological gambling in Parkinson's disease. Arch Neurol 2007; 64:212-216. This case-control study identifies factors associated with pathological gambling.
14. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 1999; 89:1369-1376.
15. Koran LM, Faber RJ, Aboujaoude E, et al. Estimating compulsive buying behavior in the United States. Am J Psychiatry 2006; 163:1806-1812.
16. Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson. Neurology 2005; 65:1570-1574.
17. Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007; 315: 1267-1270. This PET study of a rat model with trait impulsivity demonstrates that the availability of D2 and D3 receptors associated with impulse control may be an underlying susceptibility to cocaine addiction.
18. Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001; 158:2015-2021.
19. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I: A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303:791-804.
20. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62:1377-1381.
21. Fox SH, Visanji NP, Johnston TH, et al. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 2006; 63:1343-1344.
22. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59:852-858. This PET study demonstrates increased ventral striatal dopamine release in response to an acute levodopa challenge in Parkinson's disease patients with compulsive medication use. This suggests a role for neuronal sensitization with chronic levodopa use in vulnerable individuals.
23. Juncos JL, Engber TM, Raisman R, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989; 25:473-478.
24. Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ. Punding and dyskinesias. Mov Disord 2006; 21:2214-2217.
25. Pierce RC, Bell K, Duffy P, Kalivas PW. Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J Neurosci 1996; 16:1550-1560.
26. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005; 162:1414-1422.
27. Hollerman JR, Schultz W. Dopamine neurons report an error in the temporal prediction of reward during learning. Nat Neurosci 1998; 1:304-309.
28. Fiorillo CD, Tobler PN, Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science 2003; 299:1898-1902.
29. Pessiglione M, Seymour B, Flandin G, et al. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006; 31: 1042-1045. This functional MRI study examines the neural correlates of the dopaminergic outcome prediction error signal during reward and aversive learning in healthy volunteers under conditions of acute levodopa and haloperidol challenge.
30. Jentsch JD, Olausson P, De La Garza R, Taylor JR. Impairments of reversal learning and response perseveration after repeated, intermittent cocaine administrations to monkeys. Neuropsychopharmacology 2002; 26:183-190.
31. Cools R, Lewis SJ, Clark L, et al. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007; 32:180-189.
32. Richards JB, Sabol KE, de Wit H. Effects of methamphetamine on the adjusting amount procedure, a model of impulsive behavior in rats. Psychopharmacology (Berl) 1999; 146:432-439.
33. Winstanley CA, Theobald DE, Dalley JW, Robbins TW. Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders. Neuropsychopharmacology 2005; 30:669-682.
34. Frank MJ, Seeberger LJ, O'Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004; 306:1940-1943.
35. Cools R, Stefanova E, Barker RA, et al. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125:584-594.
36. Cools R, Barker RA, Sahakian BJ, Robbins TW. Mechanisms of cognitive set flexibility in Parkinson's disease e. Brain 2001; 124:2503-2512.
37. Goudriaan AE, Oosterlaan J, de Beurs E, van den Brink W. Neurocognitive functions in pathological gambling: a comparison with alcohol dependence. Tourette syndrome and normal controls. Addiction 2006; 101:534-547.
38. Tippmann-Peikert M, Park JG, Boeve BF, et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68:301-303.
39. Allam MF, Campbell MJ, Hofman A, et al. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord 2004; 19:614-621.
40. Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77:317-321.
41. Potenza MN. Should addictive disorders include nonsubstance-related conditions? Addiction 2006; 101 (Suppl 1):142-151.
42. Potenza MN, Leung HC, Blumberg HP, et al. An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003; 160:1990-1994.
43. Reuter J, Raedler T, RoseM, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005; 8:147-148.
44. Stojanov W, Karayanidis F, Johston P, et al. Disrupted sensory gating in pathological gambling. Biol Psychiatry 2003; 54:474-484.
45. Bergh C, Eklund T, Sodersten P, Nordin C. Altered dopamine function in pathological gambling. Psychol Med 1997; 27:473-475.
46. Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006; 67: 1258-1261.
47. Slutske WS, Eisen S, True WR, et al. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry 2000; 57:666-673.
48. Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006; 21:1941-1946. This case series discusses the use and pathophysiological implications of STN DBS in highly selected Parkinson's disease patients with active pathological gambling not amenable to medication changes.
49. Smeding HM, Goudriaan AE, Foncke EM, et al. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007; 78:517-519.